Table 1. Clinical 30-day Outcomes of the PARAGON, PRISM, PRIS, M-PLUS and PURSUIT Trials of GP IIb/IIIa Inhibitors in Patients with Unstable Angina and Non-Q Wave Myocardial Infarction.39,40,41,42
| Characteristic | PARAGON (Lamifiban) | PRISM (Tirofiban) | PRISM-PLUS (Tirofiban) | PURSUIT (Eptifibatid) |
| Number of patients | 2,282 | 3,231 | 1,570 | 10,948 |
| Overall death and MI at 30 days (%) | Placebo: 11.7 Drug: 10.6 |
Placebo: 7.1 Drug: 5.8 |
Placebo: 11.9 Drug: 8.7 |
Placebo: 15.7 Drug: 14.2 |
| Relative reduction | 9% | 18% | 27% | 10% |
| Major bleeding | Placebo: 3% Drug: 3% |
Placebo: 0.4% Drug: 0.4% |
Placebo: 0.8% Drug: 1.4% |
Placebo: 1.3% Drug: 3% |